Galantamine

Generic Name: Galantamine

Brand Names: Razadyne

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₁NO_₃

CAS Number: 357-70-0

Unique Ingredient Identifier: 0D3Q044KCA

Background: Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sources, such as Galanthus nivalis. Galantam...

Indication: Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer’s type.

Associated Conditions: Mild to Moderate Dementia Due to Alzheimer's Disease, Mild Dementia of the Alzheimer's Type, Moderate Alzheimer's Type Dementia

Associated Therapies: -

Clinical Trials

Efficacy of Galantamine to Treat Schizophrenia

Phase 4

Terminated

Conditions: Schizophrenia
Psychotic Disorder

Interventions: Drug: galantamine

First Posted Date: 2005-10-04

Last Posted Date: 2008-07-31

Lead Sponsor: Seattle Institute for Biomedical and Clinical Research

Target Recruit Count: 21

Registration Number: NCT00232349

Locations: 🇺🇸
VA Puget Sound Health Care System, American Lake Division, Tacoma, Washington, United States

Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies

Phase 3

Completed

Conditions: Lewy Body Disease

First Posted Date: 2005-10-03

Last Posted Date: 2005-12-16

Lead Sponsor: Neurological Research Center

Target Recruit Count: 50

Registration Number: NCT00230997

Locations: 🇺🇸
Buffalo Insititute for Medical Research, Buffalo, New York, United States
🇺🇸
Neurological Research Center, Inc., Bennington, Vermont, United States
🇺🇸
UTHSCSA Psychiatry Department, San Antonio, Texas, United States

and more 2 locations

Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke

Phase 4

Completed

Conditions: Cerebrovascular Accident

Interventions: Drug: Donepezil
Drug: Galantamine

First Posted Date: 2005-09-28

Last Posted Date: 2017-12-11

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 40

Registration Number: NCT00227994

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Safety Study of Galantamine in Tic Disorders

Phase 4

Terminated

Conditions: Tourette's Syndrome
Motor Tic Disorder
Vocal Tic Disorder

First Posted Date: 2005-09-27

Last Posted Date: 2009-08-25

Lead Sponsor: Parkinson's Disease and Movement Disorders Center

Target Recruit Count: 1

Registration Number: NCT00226824

Locations: 🇺🇸
Parkinson's Disease and Movement Disorders Center of Albany Medical Center, Albany, New York, United States

Galantamine in the Treatment of Post-Traumatic Headache

Phase 4

Conditions: Post-Traumatic Headache
Head Trauma,Closed
Retention Disorders,Cognitive

First Posted Date: 2005-09-22

Last Posted Date: 2005-09-22

Lead Sponsor: Rapoport, Alan, M.D.

Target Recruit Count: 30

Registration Number: NCT00219869

Locations: 🇺🇸
The New England Center for Headache, Stamford, Connecticut, United States

Galantamine Executive Function in Parkinson's Disease

Not Applicable

Conditions: Parkinson's Disease

First Posted Date: 2005-09-21

Last Posted Date: 2007-05-07

Lead Sponsor: Memorial Hospital of Rhode Island

Target Recruit Count: 90

Registration Number: NCT00211588

Locations: 🇺🇸
Memorial Hospital of RI, Pawtucket, Rhode Island, United States

A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder

Phase 4

Completed

Conditions: Bipolar Disorder

Interventions: Drug: Placebos
Drug: Galantamine

First Posted Date: 2005-09-20

Last Posted Date: 2017-04-18

Lead Sponsor: Cambridge Health Alliance

Target Recruit Count: 30

Registration Number: NCT00195845

Locations: 🇺🇸
Cambridge Health Alliance, Cambridge, Massachusetts, United States

Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia

Phase 4

Completed

Conditions: Schizoaffective Disorder
Schizophrenia

Interventions: Drug: galantamine

First Posted Date: 2005-09-15

Last Posted Date: 2020-12-16

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 117

Registration Number: NCT00176423

Locations: 🇺🇸
Maryland Psychiatric Research Center, Baltimore, Maryland, United States

Treatment of Tardive Dyskinesia With Galantamine

Phase 4

Completed

Conditions: Tardive Dyskinesia

First Posted Date: 2005-09-14

Last Posted Date: 2005-09-14

Lead Sponsor: Caroff, Stanley N., M.D.

Target Recruit Count: 36

Registration Number: NCT00164242

Locations: 🇺🇸
Philadelphia VA Medical Center, Philadelphia, Pennsylvania, United States

An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms

Not Applicable

Completed

Conditions: Chronic Schizophrenia

First Posted Date: 2005-09-12

Last Posted Date: 2022-03-17

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 20

Registration Number: NCT00161044

Locations: 🇺🇸
Maryland Psychiatric Research Center, Catonsville, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy